Protease inhibitors as antiviral agents

Clinical Microbiology Reviews

Volumn 11, Issue 4, 1998, Pages 614-627

  Patick, A K ^a   Potts, K E ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AG 6084; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BENZOXAZINONE DERIVATIVE; BETA LACTAM; GANCICLOVIR; INTERCELLULAR ADHESION MOLECULE 1; LAMIVUDINE; NUCLEOSIDE ANALOG; PHENANTHRENE DERIVATIVE; PLECONARIL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZOLIDINE DERIVATIVE; TRIPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; VIRUS ENZYME; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DNA SYNTHESIS INHIBITION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DESIGN; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME STRUCTURE; HEPATITIS C VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INTRANASAL DRUG ADMINISTRATION; NEPHROLITHIASIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PICORNAVIRUS; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS GENOME; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

DNA VIRUSES; HEPATITIS C VIRUS; HERPES; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN RHINOVIRUS SP.; PICORNAVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0031736007     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.11.4.614     Document Type: Review

References (170)

1. Reference deleted.
2. Abood, N. A., L. A. Schretzman, D. L. Flynn, K. A. Houseman, A. J. Wittwer, V. M. Dilworth, P. J. Hippenmeyer, and B. C. Holwerda. 1997. Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture. Bioorg. Med. Chem. Lett. 7:2105-2108.
3. Allaire, M., M. M. Chernaia, B. A. Malcom, and M. N. James. 1994. Picornaviral 3C cycteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 369:72-76.
4. Alter, M. J. 1995. Epidemiology of hepatitis C in the west. Semin. Liver Dis. 15:5-14.
5. Appelt, K. 1997. Inhibitors of HIV-1 protease, p. 1-39. In P. Veerapandian (ed.), Structure-based drug design. Marcel Dekker, Inc., New York, N.Y.
6. Arruda, E., and F. G. Hayden. 1995. Clinical studies of antiviral agents for picornaviral infections, p. 321-355. In D. J. Jeffries and E. De Clerq (ed.), Antiviral chemotherapy. John Wiley & Sons, Ltd., Chichester, United Kingdom.
7. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67:3835-3844.
8. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1994. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J. Virol. 68:5045-5055.
9. Bauer, D. J. 1955. The antiviral and synergic actions of isatin ithiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br. J. Exp. Pathol. 36:105-114.
10. Baum, E. Z., G. A. Bebernitz, J. D. Hulmes, V. P. Muzithras, T. R. Jones, and Y. Gluzman. 1993. Expression and analysis of the human cytomegalovirus UL80-encoded protease: identification of autoproteolytic sites. J. Virol. 67:497-506.
11. Baum, E. Z., W. D. Ding, M. M. Siegel, J. D. Hulmes, G. A. Bebernitz, L. Sridharan, K. Tabei, G. Krishnamurthy, T. Carofiglio, J. T. Groves, J. D. Bloom, M. DiGrandi, M. Bradley, G. Ellestad, A. P. Seddon, and Y. Gluzman. 1996. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation. Biochemistry 35:5847-5855.
12. Baum, E. Z., M. M. Siegel, G. A. Bebernitz, J. D. Hulmes, L. Sridharan, L. Sun, K. Tabei, S. H. Johnston, M. J. Wildey, J. Nygaard, T. R. Jones, and Y. Gluzman. 1996. Inhibition of human cytomegalovirus UL80 protease by specific intramolecular disulfide bond formation. Biochemistry. 35:5838-5846.
13. Bechtold, C. M., A. K. Patick, M. Alam, J. Greytok, J. A. Tino, P. Chen, E. Gordon, S. Ahmad, J. C. Barrish, R. Zahler, P. F. Lin, and R. Colonno. 1995. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob. Agents Chemother. 39:374-379.
14. Behrens, S.-E., L. Tomei, and R. DeFrancesco. 1996. Identification and properties of the RNA-dependcnt RNA polymerase of hepatitis C virus. EMBO J. 15:12-22.
15. Borin, M. T., Y. Wang, D. W. Schneck, H. Li, J. E. Brewer, and C. L. Daenzer. 1998. Multiple-dose, safety, tolerance and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers, abstr. 648, p. 201. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
16. Burck, P. J., D. H. Berg, T. P. Luk, L. M. Sassmannshausen, M. Wakulchik, D. P. Smith, H. M. Hsiung, G. W. Becker, W. Gibson, and E. C. Villareal. 1994. Human cytomegalovirus maturational proteinase: expression in Escherichia coli, purification, and enzymatic characterization by using peptide substrate mimics of natural cleavage sites. J. Virol. 68:2937-2946.
17. Cameron, D. W., A. Japour, J. W. Mellors, C. Farthing, C. Cohen, M. Markowitz, D. Poretz, S. Follansbee, D. Ho, D. McMahon, J. Berg, J. Nieves, Y. Xu, R. Rode, M. Salgo, J. Leonard, and E. Sun. 1998. Antiretroviral safety and durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two of follow-up, abstr. 388, p. 152. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
18. Carpenter, C., M. A. Fischl, S. M. Hammer. M. S. Hirsch, D. M. Jacobsen, D A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1997. JAMA 277:1962-1969.
19. Carr, A., and D. A. Cooper. 1996. HIV protease inhibitors. AIDS 10:S151-S157.
20. Carrasco, L. 1994. Picornavirus inhibitors. Pharmacol. Ther. 64:119-128.
21. Cassady, K. A., and R. J. Whitley. 1997. New therapeutic approaches to the alphaherpesvirus infections. J. Antimicrob. Chemother. 39:119-128.
22. Chambers, T. J., R. C. Weir, A. Grakoui, D. W. Court, J. F. Bazan, R. J. Fletterick, and C. M. Rice. 1990. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl. Acad. Sci. USA 87:8898-8902.
23. Chen, P., H. Tsuge, R. J. Almassay, C. L. Gribskov, S. Katoh, D. L. Vanderpool, S. A. Margosiak, C. Pinko, D. A. Matthews, and C.-C. Ran. 1996. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 86:835-843.
24. Chen, Z., H. B. Schock, D. Hall, E. Chen, and L. C. Kuo. 1995. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J. Biol. Chem. 270:21433-21436.
25. Cho, Y.-G., H.-S. Moon, and Y.-C. Sung. 1997. Construction of hepatitis C-SIN virus recombinants with replicative dependency on hepatitis C virus serine protease activity. J. Virol. Methods 65:201-207.
26. Chu, M., R. Mierzwa, I. Truumees, A. King, M. Patel, R. Berrie, A. Hart, N. Butkiewicz, B. D. Mahapatra, T.-M. Chan, and M. S. Puar. 1996. Structure of Sch 68631: a new hepatitis C proteinase inhibitor from Stretomyces sp. Tetrahedron Lett. 37:7229-7232.
27. Clendeninn, N., B. Quart, R. Anderson, M. Knowles, and Y. Chang. 1998. Analysis of long-term virologie data from the VIRACEPT® 511 protocol using 3 HIV-RNA assays, abstr. 372, p. 148. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
28. Collier, A. C., R. W. Coombs, D. A. Schoenfeld, R. L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V. J. McAuliffe, H. M. Friedman, T. C. Merigan, R. C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 334:1011-1017.
29. Conant, M., M. Markowitz, A. Hurley, D. Ho, J. Peterkin, and S. Chapman. 1996. A randomized phase II dose range-finding study of the HIV protease inhibitor VIRACEPT® as monotherapy in HIV positive patients, abstr. 2129, p. 286. In Abstracts of the XI International Conference on AIDS.
30. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
31. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, and M. Shivaprakash. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
32. Couch, R. B. 1990. Rhinoviruses, p. 607-629. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
33. Craig, C., E. O'Sullivan, and N. Cammack. 1998. Increased exposure to the HIV protease inhibitor saquinavir (SOV) does not alter the nature of key resistance mutations, abstr. 398. p. 154. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
34. Craig, J. C., I. B. Duncan, S. Gilbert, H. Jacobsen, R. Jupp, A. Moffatt, E. Race, N. A. Roberts, J. S. Mills, J. Mous, J. Sheldon, P. W. Tomlinson, and L. N. Whittaker. 1996. Treatment with saquinavir (Invirase™) should leave the majority of patients the option to use other HIV proteinase inhibitors, abstr. 32, p. 32. In Abstracts of the 5th International Workshop: HIV Drug Resistance.
35. Deeks, S. G., M. Smith, M. Holodniv, and J. O. Kahn. 1997. HIV-1 protease inhibitors. JAMA 277:145-153.
36. De Pasquale, M. P., R. Murphy, R. Gulick, L. Smeaton, J.-P. Sommadossi, V. Degruttola, A. Caliendo, D. Kuritzkes, L. Sutton, A. Savara, and R. D'Aquila. 1998. Mutations selected in HIV plasma RNA during 141W94 therapy, ahstr. 546, p. 182. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
37. Diana G. D., and D. C. Pevear. 1997. Antipicornavirus drugs: current status, p. 401-408. International Medical Press Ltd., London, United Kingdom.
38. Dimasi, N., F. Martin, C. Volpari, M. Brunetti, G. Biasiol, S. Altamura, R. Cortese, R. de Francesco, C. Steinkühler, and M. Sollazzo. 1997. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J. Virol. 71:7461-7469.
39. Dong, B. J., C. Gruta, J. Legg, K. Balano, and R. H. Goldschmit. 1998. Diabetes and use of protease inhibitors, abstr. 416. p. 157. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
40. Dougherty, W. G., and B. L. Semler. 1993. Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol. Rev. 57:781-822.
41. Dragovich, P. S., S. E. Webber, R. E. Babine, S. A. Fuhrman, A. K. Patick, D. A. Matthews, C. A. Lee, S. H. Reich, T. J. Prins, J. T. Marakovits, E. S. Littlefleld, R. Zhou, J. Tikhe, C. E. Ford, M. Wallace, J. W. Meador, R. A. Ferre, E. L. Brown, S. L. Binford, J. E. V. Harr, D. M. DeLisle, and S. T. Worland. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J. Med. Chem. 48:2806-2818.
42. Dragovich, P. S., S. E. Webber, R. E. Babine, S. A. Fuhrman, A. K. Patick, D. A. Matthews, S. H. Reich, J. T. Marakovits, T. J. Prins, R. Zhou, J. Tikhe, E. S. Littlefield, T. M. Bleckman, M. Wallace, T. Little, C. E. Ford, J. W. Meador, R. A. Ferre, E. L. Brown, S. L. Binford, D. M. DeLisle, and S. T. Worland. 1998. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J. Med. Chem. 41:2819-2834.
43. Eckart M. R., M. Selby, F. Masiarz, C. Lee, K. Berger, C. Crawford, C. Kuo, G. Kuo, M. Houghton, and Q.-L. Choo. 1993. The hepatitis C virus encodes a serine proteinase involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem. Biophys. Res. Commun. 192:399-406.
44. Erickson, J. W., and S. K. Burt. 1996. Structural mechanisms of HIV drug resistance Annu. Rev. Pharmacol. Toxicol. 36:545-571.
45. Failla, C., L. Tomei, and R. DeFrancesco. 1994. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68:3753-3760.
46. Filocamo, G., L. Pacini, and G. Migliaccio. 1997. Chimeric Sindbis viruses dependent on the NS3 protease of hepatitis C virus. J. Virol. 71:1417-1427.
47. Finzi D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
48. Ford, C. E., S. Binford, S. Fuhrman, S. E. Webber, K. Okano, and A. K. Patick. 1997 Rhinovirus 3C protease inhibitors are efficacious against several related picornaviruses, abstr. 173, p. 34:A90. In Abstracts of the 10th International Conference on Antiviral Research.
49. Fromtling, R. A., and J. Castañer. 1997. VP-63843 Pleconaril WIN-63843. Drugs Future 22:40-44.
50. Gao, M., L. Matusick-Kumar, W. Hurlburrt, S. F. DiTusa, W. W. Newcomb, J. C. Brown, P. J. McCann III, I. Deckman, and R. J. Colonno. 1994. The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. J. Virol. 68:3702-3712.
51. Gathe J., Jr., B. Burkhardt, P. Hawley, M. Conant, J. Peterkin, and S. Chapman. 1996. A randomized phase II study of VIRACEPT®, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone, abstr. 413. In Abstracts of the XI International Conference on AIDS.
52. Gibson, W. 1996. Structure and assembly of the virion. Intervirology 39: 389-400.
53. Gorbalenya, A. E., V. M. Blinov, and A. P. Donchenko. 1986. Poliovirus-encoded proteinase 3C: a possible evolutionary link between cellular senne and cysteine proteinase families. FEBS Lett. 194:253-259.
54. Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993. A second hepatitis C virus-encoded proteinase. Proc. Natl. Acad. Sci. USA 90:10583-10587.
55. Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993 Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage site. J. Virol. 67:2832-2843.
56. Hahm, B., S. H. Back, T. G. Lee, E. Wimmer, and S. K. Jang. 1996. Generation of a novel poliovirus with a requirement of hepatitis C virus protease NS3 activity. Virology 226:318-326.
57. Hammer, S. M., D. A. Katzenstein, M. D. Hughes, H. Gendacker, R. T. Schooley, R. H. Haubrich, W. K. Henry, M. M. Lederman, J. P. Phair, M. Nui, M. S. Hirsch, and T. C. Merigan. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N. Engl. J. Med. 355:1081-1090.
58. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
59. Hamre, D., J. Bernstein, and R. Donovick. 1950. Activity of p-ammobenzaldehyde, 3-thiosemicarbazone in the chick embryo and in the mouse. Proc. Soc. Exp. Biol. Med. 73:275-278.
60. Heinz, B. A., J. Tang, J. M. Labus, F. W. Chadwell, S. W. Kaldor, and M. Hammond. 1996. Simple in vitro translation assay to analyze inhibitors of rhinovirus proteases. Antimicrob. Agents Chemother. 40:267-270.
61. Henry, K., E. Kane, H. Melroe, J. Simpson, A. Patick, and D. Winslow. 1997. Experience with a ritonavir/saquinavir based regimen for the treatment of HIV-infection in subjects developing increased viral loads while receiving nelfinavir, abstr. I-204, p. 282. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
62. Hertogs, K., J. W. Mellors, P. Schel, A. V. Cauwenberghe, B. Larder, S. Kemp, V. Miller, S. Staszewski, M. Conant, and R. Pauwels. 1998. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates, abstr. 395, p. 153. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
63. Hertogs, K., A. Patick, P. Schel, A. Van Cauwenberge, M. Markowitz, D. Kuritzkes, B. Anderson, and R. Pauwels. 1997. Phenotypic resistance testing (PR-RT-Antivirogram™) of clinical HIV-1 isolates confirms the unique and different resistance pathway of nelfinavir, abstr. 906-Latebreaker. In Abstracts of the Sixth European Conference on Clinical Aspects and Treatment of HIV-infection.
64. Hijikata, M., H. Mizushima, T. Akagi, S. Mori, N. Kakiuchi, N. Kato, T. Tanaka, K. Kimura, and K. Shimotohno. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of the hepatitis C virus. J. Virol. 67:4665-4675.
65. Hirowatari, Y., M. Hijikata, and K. Shimotohno. 1995. A novel method for analysis of viral proteinase activity encoded by hepatitis C virus in cultured cells. Anal. Biochem. 225:113-120.
66. Ho, D. D., A. U. Neuman, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
67. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C.-M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68: 2016-2020.
68. Hodge, C. N., P. E. Aldrich, L. T. Bacheler, C. H. Chang, C. J. Eyermann, S. Garber, M. Grubb, D. A. Jackson, P. K. Jadhav, B. Korant, P. Y. Lam, M. B. Maurin, J. L. Meek, M. J. Otto, M. M. Rayner, C. Reid, T. R. Sharpe, L Shum D. L. Winslow, and S. Erickson-Viitanen. 1996. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem. Biol. 3:301-314.
69. Holskin, B. P., M. Bukhtiyarova, B. M. Dunn, P. Baur, J. de Chastonay, and M. W. Pennington. 1995. A continuous fluorescence-based assay of human cytomegalovirus protease using a peptide substrate. Anal. Biochem. 227: 148-155.
70. Holwerda B. C., A. J. Wittwer, K. L. Duffin, C. Smith, M. V. Toth, L. S. Carr, R. C. Wiegand, and M. L. Bryant. 1994. Activity of two-chain recombinant human cytomegalovirus protease. J. Biol. Chem. 269:25911-25915.
71. Ives, K. J., H. Jacobsen, S. A. Galpin, M. M. Garaev, L. Dorrell, J. Mous, K. Bragman, and J. N. Weber. 1997. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39:771-779.
72. Jacobsen, H., M. Hänggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J. Infect. Dis. 173:1379-1387.
73. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
74. Kahn, J. O., S. W. Lagakos, D. D. Richman, A. Cross, C. Pettinelli, S. H. Liou, M. Brown, P. A. Volberding, C. S. Crumpacker, G. Beall, et al. 1992. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N. Engl. J. Med. 327:581-587.
75. Kaldor, S. W., M. Hammon, B. A. Dressman, J. M. Labus, F. W. Chadwell, A. D. Kline, and B. A. Heinz. 1995. Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease. Bioorg. Med. Chem. Lett. 5:2021-2026.
76. Kaldor, S. W., V. J. Kalish, J. F. Davies II, B. V. Shetty, J. E. Fritz, K. Appelt, J. A. Burgess, K. M. Campanale, N. Y. Chirgadze, D. K. Clawson, B. A. Dressman, S. D. Hatch, D. A. Khalil, M. B. Kosa, P. P. Lubbehusen, M. A. Myesing, A. K. Patick, S. H. Reich, K. S. Su, and J. H. Tatlock. 1997. VIRACEPT® (Nelfinavir Mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979-3985.
77. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
78. Kay, J., and B. M. Dunn. 1990. Viral proteinases: weakness in strength. Biochim. Biophys. Acta 1048:1-18.
79. Kean, K. M., M. T. Howell, S. Grünert, M. Girard, and R. J. Jackson. 1993. Substitution mutations at the putative catalytic triad of the poliovirus 3C protease have differential effects on cleavage at different sites. Virology 194:360-364.
80. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
81. Keruly, J. C., R. E. Chaisson, and R. D. Moore. 1998. Diabetes and hyperglycemia in patients receiving protease inhibitors, abstr. 415, p. 157. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
82. Kim, J. L., K. A. Morgenstern, C. Lin, T. Fox, M. D. Dwyer, J. A. Landro, S. P. Chambers, W. Markland, C. A. Lepre, E. T. O'Malley, S. L. Harbeson, C. M. Rice, M. A. Murcko, P. R. Caron, and J. A. Thomson. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355.
83. Koch, J. O., and R. Bartenschlager. 1997. Determinants of substrate specificity in the NS3 serine proteinase of the hepatitis C virus. Virology 237: 78-88.
84. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
85. Kolykhalov, A. A., E. V. Agapov, K. J. Blight, K. Mihalik, S. M. Feinstone, and C. M. Rice. 1997. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570-574.
86. Kräusslich, H.-G., and E. Wimmer. 1988. Viral proteinases. Annu. Rev. Biochem. 57:701-754.
87. Lagacé, L., F. Dô, E. Malenfant, R. Déziel, and M. G. Cordingley. 1998. Inhibition of proteinase dependent processing of the scaffold proteins of HCMV capsid by monocyclic β-lactams, abstr. 158, poster. In Abstracts of the 11th International Conference on Antiviral Research.
88. Lal, R., A. Hsu, G. R. Granneman, T. El-Shourbagy, M. Johnson, W. Lam, L. Manning, A. Japour, and E. Sun. 1998. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir, abstr. 647, p. 201. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
89. Lam, P. Y., P. K. Jadhav, C. J. Eyermann, C. N. Hodge, Y. Ru, L. T. Bacheler, J. L. Meek, M. J. Otto, M. M. Tayner, Y. N. Wong, et al. 1994. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263:380-384.
90. Lawrence, J., J. Schapiro, M. Winters, J. Montoya, A. Zolopa, R. Pesano, D. Winslow, and T. C. Merigan. 1998. Salvage therapy with indinavir plus nevirapine in patients previously treated with two other protease inhibitors and multiple reverse transcriptase inhibitors, abstr. 422, p. 158. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
91. Lawson, M. A., and B. L. Semler. 1990. Picornavirus protein processing -enzymes, substrates, and genetic regulation. Curr. Top. Microbiol. Immunol. 161:49-80.
92. Lazdins, J. K., J. Mestan, G. Goutte, M. R. Walker, G. Bold, H. G. Capraro, and T. Klimkait. 1997. In vitro effect of alpha-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175:1063-1070.
93. Lin, C., and C. M. Rice. 1995. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. Proc. Natl. Acad. Sci. USA 92:7622-7626.
94. Lin, C., J.-W. Wu, K. Hsiao, J. A. Thompson, and M. S.-S. Su. 1997. A novel, highthroughput assay system for the hepatitis C virus NS3 serine proteinase in cos cells, abstr. 101, p. 101. In Abstracts of the 4th International Meeting on Hepatitis C Virus and Related Viruses.
95. Love, R. A., H. E. Parge, J. A. Wickersham, Z. Hostomsky, N. Habuka, E. W. Moomaw, T. Adachi, and Z. Hostomska. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342.
96. Mann, M., T. Piazza-Hepp, E. Koller, and C. Gibert. 1998. Abnormal fat distribution in AIDS patients following protcase inhibitor therapy, abstr. 412, p. 157. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
97. Margosiak, S. A., D. L. Vanderpool, W. Sisson, C. Pinko, and C.-C. Ran. 1996. Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer. Biochemistry 35: 5300-5307.
98. Markowitz, M., M. Conant, A. Hurley, R. Schluger, M. Duran, J. Peterkin, S. Chapman, A. Patick, A. Henricks, G. J. Yuen, W. Hoskins, N. Clendennin, and D. D. Ho. A preliminary evaluation of nelfinavir mesylate, an inhibitor of HIV-1 protease, to treat HIV infection. J. Infect. Dis., in press.
99. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. Narayana Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
100. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
101. Martell, M., J. I. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, J. Guardia, and J. Gomez. 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66:3225-3229.
102. Martin, J. A. 1992. Recent advances in the design of HIV proteinase inhibitors. Antiviral Res. 17:265-278.
103. Matthews, D. A., W. W. Smith, R. A. Ferre, B. Condon, G. Budahazi, W. Sisson, J. E. Villafranca, C. A. Janson, H. E. McElroy, C. L. Gribskov, and S. Worland. 1994. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77:761-771.
104. McDonald, C. K., and D. R. Kuritzkes. 1997. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157:951-959.
105. McKinlay, M. A., D. C. Pevear, and M. G. Rossmann. 1992. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu. Rev. Microbiol. 46:635-654.
106. Melnick, J. L. 1990. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p. 549-605. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
107. Merry, C., M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tjia, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
108. Mocarski, E. S., Jr. 1996. Cytomegaloviruses and their replication, p. 2447-2492. In B. N. Fields and D. M. Knipe (ed.), Virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
109. Molla, A., M. Korneyeva, Q. Can, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
110. Morris-Jones, S., G. Moyle, and P. J. Easterbrook. 1997. Antiretroviral therapies in HIV-1 infection. Expert Opin. Investig. Drugs. 6:1049-1061.
111. Mueller, B. U. 1997. Antiviral chemotherapy. Curr. Opin. Pediatr. 9:178-183.
112. Murphy, R., V. Degruttola, R. Gulick, R. D'Aguila, J. Eron, J. P. Sommadossi, L. Smeaton, J. Currier, R. Tung, and D. Kuritzkes. 1998. 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347, abstr. 512, p. 175. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
113. Nascimbeni, M., S. Paulous, and F. Clavel. 1998. Single-cycle parameters of the inhibition of HIV infectivity by protease inhibitors, abstr. 406, p. 155. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
114. O'Boyle, D. R. I., K. Wager-Smith, J. T. Stevens, and S. P. Weinheimer. 1995. The effect of internal autocleavage on kinetic properties of the human cytomegalovirus protease catalytic domain. J. Biol. Chem. 270:4753-1758.
115. Otto, M. J., C. D. Reid, S. Garber, P. Y.-S. Lam, H. Scarnati, L. T. Bacheler, M. M. Rayner, and D. L. Winslow. 1993. In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob. Agents Chemother. 37:2606-2611.
116. Palmer, S., R. Shafer, and T. C. Merigan. 1998. Highly drug-resistant HIV-1 isolates are cross resistant to many of the current anti-HIV compounds in clinical development, abstr. 405, p. 155. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
117. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity of hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
118. Patick, A. K., T. J. Boritzki, and L. A. Bloom. 1997. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob. Agents Chemother. 41:2159-2164.
119. Patick, A, K., C. Ford, S. Binford, S. Fuhrman, M. Brothers, J. Meador, S. E. Webber, K. Okano, L. Zalman, and S. Worland. 1997. Evaluation of the antiviral activity and cytotoxicity of peptidic inhibitors of human rhino-virus 3C protease, a novel target for antiviral intervention, abstr. 116. In Abstracts of the 10th International Conference on Antiviral Research.
120. Patick, A. K., D. Kuritzkes, V. A. Johnson, D. Shugarts, M. Bakhtiari, K. E. Potts, A. Farnsworth, R. Anderson, J. L. Koel, J. D. Hazelwood, C. D. Nail, M. Duran, M. Markowitz, D. Ho, and D. Richman. 1997. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other HIV-1 protease inhibitors, abstr. 18, p. 12. In Abstracts of the International Workshop on HIV Drug Resistance. Treatment Strategies and Eradication.
121. Patick, A. K., M. Duran, Y. Cao, D. Shugarts, M. R. Keller, E. Mazabel, M. Knowles, S. Chapman, D. R. Kuritzkes, D. D. Ho, and M. Markowitz. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus tvpe 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:2637-2644.
122. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297.
123. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hennsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P.-F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
124. Peng, C., B. K. Ho, T. W. Chang, and N. T. Chang. 1989. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63:2550-2556.
125. Perelson, A. S., A. U. Neuman, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time. Science 271:1582-1586.
126. Pinko, C., S. A. Margosiak, D. Vaderpool, J. C. Gutowski, B. Condon, and C.-C. Kan. 1995. Single-chain recombinant human cytomegalovirus pro-tease. J. Biol. Chem. 270:23634-23640.
127. Poppe, S. M., D. E. Slade, K.-T. Chong, R. R. Hinshaw, P. J. Pagano, M. Markowitz, D. D. Ho, H. Mo, R. R. German III, T. J. Dueweke, S. Thaisrivongs, and W. G. Tarpley. 1997. Antiviral activity of the dihydropyrone PNU-140690. a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41:1058-1063.
128. Oiu X., J. S. Culp, A. G. DiLella, B. Hellmig, S. S. Hoog, C. A. Janson, W. W. Smith, and S. S. Abdel-Meguid. 1996. Unique fold and active site in cytomegalovirus protease. Nature 383:275-278.
129. Ralston, R., K. Thudium, K. Berger, C. Kuo, B. Gervase, J. Hall, M. Selby, G. Kuo, M. Houghton, and Q.-L. Choo. 1993. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J. Virol. 67:6753-6761.
130. Rice, C. M. 1996 Flaviviridae: the viruses and their replication, p. 931-959. In B. N. Fields and D. M. Knipe (ed.). Virology, 3rd ed. Lippincott-Raven. Philadelphia, Pa.
131. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacia, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, et al. 1994. Nevirapine resistance mutation of human immunodeficiency virus type 1 selected dur ing therapy. J. Virol. 68:1660-1666.
132. Roth V. R., J. B. Angel, and S. Kravick. 1998. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors, abstr. 411, p. 156. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
133. Rueckert, R. R. 1990. Picornaviridae and their replication, p. 507-548. In B. N. Fields and D. M. Knipe (ed.), Virology. Raven Press, New York, N.Y.
134. Saag, M., M. Gersten, Y. Chang, S. L. Greenberg, G. Yu, and N. J. Clendeninn. 1997. Long term virological and immunological effect of the HIV
135. Saag M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, et al. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N. Engl. J. Med. 329:1065-1072.
136. Santolini, E., G. Migliaccio, and N. LaMonica. 1994. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J. Virol. 68: 3631-3641.
137. Saracco, G., and M. Rizzetto. 1995. The long-term efficacy of Interferon alpha in chronic hepatitis C patients: a critical review. J. Gastroenterol. Hepatol. 10:668-673.
138. Schapiro, J. M., M. A. Winters, F. Stewart, B. Efron, J. Norris, M. J. Kozal, and T. C. Merigan. 1996. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-counts in HIV-infected patients. Ann. Intern. Med. 124:1039-1050.
139. Schenk, P., A. S. Woods, and W. Gibson. 1991. The 45-kilodalton protein of cytomegalovirus (Colburn) B-capsids is an amino-terminal extension form of the assembly protein. J. Virol. 65:1525-1529.
140. Schiff, G. M., M. A. McKinlay, and J. R. Sherwood. 1996. Oral efficacy of VP 63843 in coxsackievirus A21 infected volunteers, abstr. H43, p. 93. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
141. Schmit, J.-C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter E. De Clercq, and A.-M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for one year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
142. Sension, M., R. Elion, C. Farthing, J. Currier, C. Lindquist, B. Richardson and M. Becker. 1998. Open label pilot studies to assess the safety and efficacy of bid dosing regimens of VIRACEPT® (nelfinavir mesylate) combined with NRTI's in HIV-infected treatment-naive patients, abstr. 387A, p. 151. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
143. Shieh, H.-S., R. G. Kurumbail, A. M. Stevens, R. A. Stegeman, E. J. Sturman, J. Y. Pak, A. J. Wittwer, M. O. Palmier, R. C. Wiegand, B. C. Holwerda, and W. C. Stallings. 1996. Three-dimensional structure of human cytomegalovirus protease. Nature 383:279-282.
144. Smidt M. L., K. E. Potts, S. P. Tucker, L. Blystone, T. R. Steibel, W. C. Stallings, J. J. McDonald, D. Pillay, D. D. Richman, and M. L. Bryant. 1996 A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob. Agents Chemother. 41: 515-522.
145. Spruance, S. L., A. T. Pavia, J. W. Mellors, R. Murphy, J. Gathe, Jr., E. Stool, J. G. Jemsek, P. Dellamonica, A. Cross, and L. Dunkle. 1997. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann. Intern. Med. 126:355-363.
146. Steinkuhler, C., A. Urbani, L. Tomei, G. Biasiol, M. Sardana, E. Blanchi, A. Pessi, and R. De Francesco. 1996. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J. Virol. 70:6694-6700.
147. Sudo, K., Y. Matsumoto, M. Matsushima, M. Fujiwara, K. Konno, K. Shimotohno, S. Shigeta, and T. Yokota. 1997. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem. Biophys. Res. Commun. 238:643-647.
148. Tebas, P., E. Kane, M. Klebert, J. Simpson, W. G. Powderly, and K. Henry. 1998. Virologic responses to a ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir, abstr. 510, p. 175. In Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections.
149. Threlkeld, D. S. (ed.). 1997. Facts and comparisons: loose leaf drug infor-mation service, p. 402A-407Z. Facts and Comparisons, St. Louis, Mo.
150. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Blair 1995 Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
151. Tomei, L., C. Failla, E. Santolini, R. De Francesco, and N. LaMonica. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67:4017-4026.
152. Tong, L., C. Qian, M.-J. Massariol, P. R. Bonneau, M. G. Cordingley, and L. Lagacé. 1996. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 383:272-275.
153. Turner, R. B., M. T. Wecker, G. Pohl, T. J. Witek Jr., S. Marlin, E. McNally, and F. G. Hayden. 1997. Efficacy of soluble ICAM-1 (sICAM) for prevention of rhinovirus infection and illness, abstr. H-85, p. 77. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
154. Urvil, P. T., N. Kakiuchi, D.-M. Zhou, K. Shimotohno, P. K. R. Kumar, and S. Nishikawa. 1997. Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. Eur. J. Biochem. 248:130-138.
155. Vacca, J. P. B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emmi, and J. R. Huff. 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
156. + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 29:91-93.
157. Vella, S., and L. Palmisano. 1997. Update on protease inhibitors. Antiviral Ther. 2:29-37.
158. Von der Helm, K. 1996. Retroviral proteases: structure, function and inhibition from a non-anticipated viral enzyme to the target of a most promising HIV therapy. Biol. Chem. 377:765-774.
159. Webber, S., J. Tikhe, S. T. Worland, S. A. Fuhrman, T. F. Hendrickson, D. A. Matthews, R. A. Love, A. K. Patick, J. W. Meador, R. A. Ferre, E. L. Brown, D. M. DeLisle, C. E. Ford, and S. L. Binford. 1996. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J. Med. Chem. 39:5072-5082.
160. Webber, S. E., K. Okano, T. L. Little, S. Reich, Y. Xin, S. T. Worland, S. A. Furhman, D. A. Matthews, T. F. Hendrickson, R. A. Love, A. K. Patick, J. W. Meador III, R. A. Ferre, E. L. Brown, C. E. Ford, and S. L. Binford. 1998. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: The design, synthesis, biological evaluation and cocrystal structure solution of P1 glutamine isosteric replacements. J. Med. Chem. 41:2786-2805.
161. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and E. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1. Nature 373:117-122.
162. Weiner, A. J., H. M. Geysen, C. Christopherson, J. E. Hall, T. J. Mason, G. Saracco, F. Bonino, K. Crawford, C. D. Marion, K. A. Crawford, M. Brunetto, P. J. Barr, T. Miyamura, J. McHutchinson, and M. Houghton. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA 89:3468-3472.
163. Welch, A. R., A. S. Woods, L. M. McNally, R. J. Cotter, and W. Gibson. 1991. A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl. Acad. Sci. USA 88:10792-10796.
164. Winslow, D. L., and M. J. Otto. 1995. HIV protease inhibitors. AIDS 9:S183-S192.
165. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-585.
166. Wong, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
167. Xu, J., E. Mendez, P. R. Caron, C. Lin, M. A. Murcko, M. S. Collett, and C. M. Rice. 1997. Bovine viral diarrhea virus NS3 serine proteinase: polyprotein cleavage sites, cofactor requirements, and molecular model of an enzyme essential for pestivirus replication. J. Virol. 71:5312-5322.
168. Yanagi, M., R. H. Purcell, S. U. Emerson, and J. Bukh. 1997. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. USA 94:8738-8743.
169. Zalman, L. S., M. A. Brothers, K. Okano, and S. E. Webber. 1997. A novel anti-rhinoviral compound directed at 3C protease can diminish IL-6 and IL-8 production in a transformed bronchial epithelial cell line, abstr. 172, p. A89. In Abstracts of the 10th International Conference on Antiviral Research.
170. Zhang, R., J. Durkin, W. T. Windsor, C. McNemar, L. Ramanathan, and H. V. Le. 1997. Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. J. Virol. 71:6208-6213.